Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9323580 | 0.91 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9321532 | 0.81 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5597255 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A4 | |
| SCHEMBL9320726 | 0.80 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4885001 | 0.78 | SLC6A2 (0.76) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9321165 | 0.77 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9321387 | 0.77 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10682403 | 0.77 | DRD4 (0.42) | — | |
| SCHEMBL4734906 | 0.75 | SLC6A2 (0.67) | SLC6A2 | |
| SCHEMBL4731864 | 0.74 | SLC6A2 (0.65) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551413-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | Wyeth a Corporation of the State of Delaware (US) | 2005-07-13 | — | — | EP | claimed |
| EP-1551380-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | Wyeth (US) | 2005-07-13 | — | — | EP | claimed |
| US-20050130987-A1 | Methods of treating vasomotor symptoms | WYETH (US) | 2005-06-16 | — | — | US | claimed |
| US-20040152710-A1 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH | 2004-08-05 | — | — | US | claimed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| WO-2004035058-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | claimed |
| EP-0310268-B1 | Substituted cycloalkanols | AMERICAN HOME PROD (US) | 1994-02-02 | — | — | EP | claimed |
| US-4826844-A | ANTIDEPRESSANT, ANXIOLYTIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-05-02 | — | — | US | claimed |
| US-20080227850-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2008-09-18 | — | — | US | disclosed |
| US-7345096-B2 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1846105-A2 | USE OF ADRENERGIC ALPHA2B ANTAGONISTS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | Wyeth (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1551413-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | Wyeth a Corporation of the State of Delaware (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551379-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | Wyeth (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1551380-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | Wyeth (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040143008-A1 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH | 2004-07-22 | — | — | US | disclosed |
| WO-2004035036-A1 | A METHOD OF TREATING VASOMOTOR SYMPTOMS COMPRISING A COMPOUND HAVING NOREPINEPHRINE REUPTAKE INHIBITOR ACTIVITY AND 5-HT2A ANTAGONISTIC ACTIVITY | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035035-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035058-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2004-04-29 | — | — | WO | disclosed |
| US-4826844-A | ANTIDEPRESSANT, ANXIOLYTIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0310268-A2 | Substituted cycloalkanols | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |